This was shown in studies demonstrating that long-term treatment of a NSCLC cell line with cetuximab generates cell clones that have enhanced nuclear EGFR staining.54 Similarly in BC, nuclear EGFR has been attributed to inherent resistance to cetuximab and gefitinib using various TNBC cell lines.55,56 Retrospective studies using patient-derived samples linking enhanced nuclear EGFR to clinical EGFRi resistance are yet to be performed. The gene discussed is EGFR; the disease is breast cancer.